References
- GovindanRPageNMorgenszternDChanging epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results databaseJ Clin Oncol200624284539454417008692
- XiaoXGChenYWangSJRelationship between the SER treatment period and prognosis of patients with small cell lung cancerAsian Pac J Cancer Prev201415156415641925124635
- KimHGLeeGWKangJHCombination chemotherapy with irinotecan and cisplatin in elderly patients (≥65 years) with extensive-disease small-cell lung cancerLung Cancer200861222022618272249
- ChenGHuynhMFehrenbacherLPhase II trial of irinotecan and carboplatin for extensive or relapsed small cell lung cancerJ Clin Oncol20082791401140419204194
- EttingerDSNew drugs for chemotherapy-naive patients with extensive disease small cell lung cancerSemin Oncol2001282272911479894
- LuoJWuFYLiAWComparison of vinorelbine, ifosfamide and cisplatin (NIP) and etoposide and cisplatin (EP) for treatment of advanced combined small cell lung cancer (cSCLC) patients: a retrospective studyAsian Pac J Cancer Prev20121394703470623167406
- JiangLYangKHGuanQLCisplatin plus etoposide versus other platin-based regimens for patients with extensive small-cell lung cancer: a systematic review and meta-analysis of randomised, controlled trialsIntern Med J201242121297130922530708
- NodaKNishiwakiYKawaharaMIrinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancerN Engl J Med20023462859111784874
- HermesABergmanBBremnesRIrinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trialJ Clin Oncol200826264261426718779613
- SchmittelAFischer von WeikersthalLSebastianMA randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancerAnn Oncol200617466366716423848
- SchmittelASebastianMFischer von WeikersthalLA German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancerAnn Oncol20112281798180421266516
- JiangJLiangXZhouXA meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancerJ Thorac Oncol20105686787320521354
- Di PaoloABocciGPolilloMPharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicityCurr Drug Metab2011121093294321787264
- LaraPNJrNataleRCrowleyJPhase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124J Clin Oncol200927152530253519349543
- ZatloukalPCardenalFSzczesnaAA multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive diseaseAnn Oncol20102191810181620231298
- KalemkerianGPAdvances pharmacotherapy of small-cell lung cancerExpert Opin Pharmacother201415162385239625255939
- PillaiRNOwonikokoTKSmall cell lung cancer: therapies and targetsSemin Oncol201441113314224565587
- EhrlichDWangBLuWIntratumoral anti-HuD immunotoxin therapy for small cell lung cancer and neuroblastomaJ Hematol Oncol2014719125523825
- ImaiHMoriKWakudaKProgression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancerAnn Thorac Med2015101616625593610
- LiMWangZGuoJClinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancerOnco Targets Ther20142371653166125285015
- StewartCFPanettaJCOShaughnessyMAUGT1A1 promoter genotype correlates with SN-38 pharmacokinetics but not severe toxicity in patients receiving low-dose irinotecanJ Clin Oncol200725182594260017577039